Jian-jun Han

China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Severe systemic cutaneous adverse reactions following camrelizumab therapy: a case report and literature review.

Severe systemic cutaneous adverse reactions following camrelizumab therapy: a case report and literature review.

Journal: Frontiers in immunology

Published: September 27, 2025

Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway.

Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway.

Journal: Scientific reports

Published: June 10, 2025

Multiomics reveals metformin's dual role in gut microbiome remodeling and hepatic metabolic reprogramming for MAFLD intervention.

Multiomics reveals metformin's dual role in gut microbiome remodeling and hepatic metabolic reprogramming for MAFLD intervention.

Journal: Scientific reports

Published: January 20, 2025

Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients.

Immune cell dynamics and the impact on the efficiency of transvascular antitumor interventional therapies in hepatocellular carcinoma patients.

Journal: Frontiers in immunology

Published: June 17, 2024

Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects.

Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects.

Journal: Heliyon

Published: June 01, 2024

Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.

Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.

Journal: Biochimica et biophysica acta. Reviews on cancer

Published: September 25, 2023

Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.

Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes.

Journal: Frontiers in endocrinology

Published: July 17, 2022

A systematic review and meta-analysis comparing tumor progression and complications between radiofrequency ablation and thyroidectomy for papillary thyroid carcinoma.

A systematic review and meta-analysis comparing tumor progression and complications between radiofrequency ablation and thyroidectomy for papillary thyroid carcinoma.

Journal: Frontiers in oncology

Published: July 15, 2022

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).

Journal: Signal transduction and targeted therapy

Published: June 14, 2022

Percutaneous Radiofrequency Ablation Combined With Chemotherapy Versus Chemotherapy Only for Ovarian Cancer Liver Metastasis.

Percutaneous Radiofrequency Ablation Combined With Chemotherapy Versus Chemotherapy Only for Ovarian Cancer Liver Metastasis.

Journal: Frontiers in oncology

Published: October 11, 2021

Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1.

Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1.

Journal: BMC cancer

Published: January 06, 2021

HMGB1, the Next Predictor of Transcatheter Arterial Chemoembolization for Liver Metastasis of Colorectal Cancer?

HMGB1, the Next Predictor of Transcatheter Arterial Chemoembolization for Liver Metastasis of Colorectal Cancer?

Journal: Frontiers in oncology

Published: June 14, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026